Fairmount Funds Management’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $76M | Hold |
|
|||||
|
2025
Q2 | $74.5M | Buy |
|
|||||
|
2025
Q1 | $63M | Hold |
|
|||||
|
2024
Q4 | $72.1M | Hold |
|
|||||
|
2024
Q3 | $81.8M | Hold |
|
|||||
|
2024
Q2 | $74.8M | Hold |
|
|||||
|
2024
Q1 | $56.3M | Buy |
|
|||||
|
2023
Q4 | $29.5M | Hold |
|
|||||
|
2023
Q3 | $29.1M | Buy |
|
|||||
|
2023
Q2 | $43.4M | Buy |
|
|||||
|
2023
Q1 | $42.2M | Buy |
|
|||||
|
2022
Q4 | $2.58M | Buy |
|